Urogen Pharma

URGN

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$1.1m

Combined value at quarter end

Last quarter

1 bought

0 sold or trimmed

Price at Q2 ’26 end

$36.80

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Managers holding it, by quarter

0Q4 ’23

0Q1 ’24

0Q2 ’24

0Q3 ’24

0Q4 ’24

0Q1 ’25

0Q2 ’25

0Q3 ’25

0Q4 ’25

0Q1 ’26

1Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Urogen Pharma.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Urogen Pharma

Polen Capital Management	0.0%$1.1m	$1.1m	New	1 qtr

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Urogen Pharma
		Bought or sold				Filing
8 Oct 2026	Degnan ChrisChief Financial Officer	▼ Sold	2,202	$36.69	$81k	Form 4
8 Sep 2026	Smith Jason DrewGeneral Counsel	▼ Sold	1,519	$42.54	$65k	Form 4
8 Sep 2026	Schoenberg MarkChief Medical Officer	▼ Sold	871	$42.92	$37k	Form 4
20 Aug 2026	Schoenberg MarkChief Medical Officer	▼ Sold	60,677	$47.05	$2.9m	Form 4

About the company

Sector: Health care · Pharmaceutical Preparations
Financial year ends: 31 December
Shares outstanding: 49m at 28 Jul 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

2015

$17.5m2016

$8.2m2017

$1.1m2018

$18k2019

$11.8m2020

$48.0m2021

$64.4m2022

$82.7m2023

$90.4m2024

$110m2025

Urogen Pharma revenue and net income by year
Year	Revenue	Net income
2025	$110m	−$153m
2024	$90.4m	−$127m
2023	$82.7m	−$102m
2022	$64.4m	−$110m
2021	$48.0m	−$111m
2020	$11.8m	−$128m
2019	$18k	−$105m
2018	$1.1m	−$75.7m
2017	$8.2m	−$20.0m
2016	$17.5m	−$1.9m
2015	–	−$12.7m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.